{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:07:18Z","timestamp":1791086838845,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2005,3,8]],"date-time":"2005-03-08T00:00:00Z","timestamp":1110240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2005,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Mutations in the receptor tyrosine kinase (RTK\/RAS) signalling pathway frequently provide a proliferative signal in myeloid malignancies. However, the role of <jats:italic>RASSF1A<\/jats:italic>, <jats:italic>SHP\u20101<\/jats:italic> and <jats:italic>SOCS\u20101<\/jats:italic>, negative regulators of RTK\/RAS signalling, has not been extensively investigated in the myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML). This study employed methylation\u2010specific polymerase chain reaction (MS\u2010PCR) to determine if aberrant promotor methylation of <jats:italic>RASSF1A<\/jats:italic>, <jats:italic>SHP\u20101<\/jats:italic> and <jats:italic>SOCS\u20101<\/jats:italic> is involved in the pathogenesis of myeloid malignancies. Patients with MDS (<jats:italic>n<\/jats:italic>\u2003=\u2003107), AML (<jats:italic>n<\/jats:italic>\u2003=\u2003154) and juvenile myelomonocytic leukaemia (JMML, <jats:italic>n<\/jats:italic>\u2003=\u20035) were investigated, together with 15 normal controls. Primers were located in the promotor region of each gene as well as within exon 2 of <jats:italic>SOCS\u20101<\/jats:italic>. Methylation of <jats:italic>RASSF1A<\/jats:italic> was found in five of 55 (9%) MDS cases, but not in any of 57 AML cases studied. <jats:italic>RASSF1A<\/jats:italic> methylation was present in one case (20%) of JMML. <jats:italic>SHP\u20101<\/jats:italic> methylation was present in 13 of 121 (11%) AML cases but was not found in MDS or JMML. <jats:italic>SOCS\u20101<\/jats:italic> promoter methylation was present in eight of 74 (11%) MDS patients but was not seen in JMML or AML. Importantly, <jats:italic>RAS<\/jats:italic> mutations and <jats:italic>RASSF1A<\/jats:italic> and <jats:italic>SOCS\u20101<\/jats:italic> methylation were mutually exclusive indicating that approximately 30% of MDS cases had a defect of the RTK\/RAS pathway and its negative regulation. Finally, <jats:italic>SOCS\u20101<\/jats:italic> exon 2 methylation may not be pathogenetically relevant, since it was detected in samples from normal individuals and did not correlate with promotor methylation.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2005.05412.x","type":"journal-article","created":{"date-parts":[[2005,3,21]],"date-time":"2005-03-21T14:25:52Z","timestamp":1111415152000},"page":"60-65","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Aberrant methylation of the negative regulators <i>RASSFIA<\/i>, <i>SHP\u20101<\/i> and <i>SOCS\u20101<\/i> in myelodysplastic syndromes and acute myeloid leukaemia"],"prefix":"10.1111","volume":"129","author":[{"given":"M. F.","family":"Johan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. T.","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E.","family":"Frew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. C.","family":"Goodeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. T.","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,3,21]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02850.x"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204175"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1006\/clin.1994.1185"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04362.x"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.10222"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2007"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-004-0843-1"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/77083"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206582"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205466"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1735"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01449.x"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205446"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20030407"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.18.9821"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90351-8"},{"key":"e_1_2_13_18_1","article-title":"Kit exon 8 mutations associated with core binding factor (CBF) \u2013 acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor","author":"Kohl T.M.","year":"2004","journal-title":"Blood"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04660.x"},{"key":"e_1_2_13_20_1","first-page":"3877","article-title":"High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma","volume":"61","author":"Lo K.","year":"2001","journal-title":"Cancer Research"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-04-1083"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s100380300008"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04664.x"},{"key":"e_1_2_13_24_1","first-page":"6390","article-title":"Gene silencing of the tyrosine phosphastase SHP1 by aberrant methylation in leukemias\/lymphomas","volume":"62","author":"Oka T.","year":"2002","journal-title":"Cancer Research"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205192"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng0796-309"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1515\/BC.2002.097"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0268-960X(03)00024-9"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205537"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.6.484"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C000463200"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05107.x"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-0378-3"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-1119(03)00400-1"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-3242"},{"key":"e_1_2_13_36_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ng0501-29","article-title":"SOCS\u20101, a negative regulator of the JAK\/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth\u2010suppression activity","volume":"28","author":"Yoshikawa H.","year":"2001","journal-title":"Nature Genetics"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2005.05412.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2005.05412.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T07:01:58Z","timestamp":1697439718000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2005.05412.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,21]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["10.1111\/j.1365-2141.2005.05412.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05412.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3,21]]},"assertion":[{"value":"2005-03-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}